Dr. Reddy's Laboratories Dirección

Dirección controles de criterios 3/4

El CEO de Dr. Reddy's Laboratories' es Erez Israeli, nombrado en Apr 2018, tiene una permanencia de 6.08 años. posee directamente un 0.022% de las acciones de la empresa, con un valor de $2.76M. La antigüedad media del equipo directivo y de la junta directiva es de 6.1 años y 3.8 años, respectivamente.

Información clave

Erez Israeli

Chief Executive Officer (CEO)

₹195.4m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	6.1yrs
Participación del CEO	0.02%
Permanencia media de la dirección	6.1yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements

Nov 29

Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook

Oct 27

Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed

Jan 20

Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue

Nov 07

Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M

Jul 28

Dr. Reddy's launches generic drugs for allergies in US

Jul 22

Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases

Jul 05

Dr. Reddy's in talks to bring single-dose Sputnik Light vaccine in India

May 31

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Erez Israeli en comparación con los beneficios de Dr. Reddy's Laboratories?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	₹52b
Sep 30 2023	n/a	n/a	₹51b
Jun 30 2023	n/a	n/a	₹47b
Mar 31 2023	₹195m	n/a	₹45b
Dec 31 2022	n/a	n/a	₹36b
Sep 30 2022	n/a	n/a	₹31b
Jun 30 2022	n/a	n/a	₹30b
Mar 31 2022	₹127m	n/a	₹24b
Dec 31 2021	n/a	n/a	₹26b
Sep 30 2021	n/a	n/a	₹19b
Jun 30 2021	n/a	n/a	₹17b
Mar 31 2021	₹120m	n/a	₹17b
Dec 31 2020	n/a	n/a	₹21b
Sep 30 2020	n/a	n/a	₹15b
Jun 30 2020	n/a	n/a	₹19b
Mar 31 2020	₹195m	₹107m	₹19b
Dec 31 2019	n/a	n/a	₹16b
Sep 30 2019	n/a	n/a	₹27b
Jun 30 2019	n/a	n/a	₹21b
Mar 31 2019	₹123m	n/a	₹19b

Compensación vs. Mercado: La compensación total de Erez($USD2.35M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD13.51M).

Compensación vs. Ingresos: La compensación de Erez ha aumentado más de un 20% en el último año.

CEO

Erez Israeli (55 yo)

6.1yrs

Permanencia

₹195,380,000

Compensación

Mr. Erez Israeli, MBA has been Chief Executive Officer of Dr. Reddy's Laboratories Limited since August 1, 2019. Mr. Israeli served as Chief Operating Officer, Global Head Generics & PSAI Business and Memb...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Gunupati Prasad	Co-Chairman	38.1yrs	₹187.71m	1.54% ₹ 193.4m
Kallam Reddy	Chairman of the Board & Member of the Management Council	31.3yrs	₹115.40m	4.53% ₹ 569.8m
Erez Israeli	CEO & Member of the Management Council	6.1yrs	₹195.38m	0.022% ₹ 2.8m
Parag Agarwal	CFO & Member of Management Council	3.4yrs	₹65.16m	sin datos
Deepak Sapra	CEO of API & Services & Member of Management Council	no data	₹40.12m	sin datos
Venkata Motupalli	CEO of Branded Markets - India & Emerging Countries and Member of Management Council	no data	₹80.20m	sin datos
Archana Bhaskar	EVP, Head of Corporate Communications	6.9yrs	₹63.42m	sin datos
Sanjay Sharma	Executive VP	6.8yrs	₹61.42m	sin datos
Marc Kikuchi	CEO of North America Generics & Member of Management Council	5.3yrs	₹112.49m	0.016% ₹ 2.0m
Patrick Aghanian	CEO of European Generics & Member of Management Council	no data	₹91.63m	sin datos
Mannam Venkatanarasimham	Deputy CFO & Member of the Management Council	no data	₹47.20m	sin datos
Sushrut Kulkarni	Global Head of Integrated Product Development Organisation & Member of the Management Council	no data	₹48.35m	sin datos

6.1yrs

Permanencia media

55.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de RDY es experimentado (6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Gunupati Prasad	Co-Chairman	38.1yrs	₹187.71m	1.54% ₹ 193.4m
Kallam Reddy	Chairman of the Board & Member of the Management Council	31.3yrs	₹115.40m	4.53% ₹ 569.8m
Kalpana Morparia	Lead Independent Director	16.9yrs	₹15.35m	0.0065% ₹ 815.6k
R. Rajgopalan	Member of the Scientific Advisory Board	no data	₹8.36m	sin datos
Arun Kumar	Independent Director	1.8yrs	₹10.95m	sin datos
Shikha Sharma	Additional Independent Director	5.3yrs	₹13.15m	sin datos
K. Reddy	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Leo Puri	Independent & Non Whole-time Director	5.6yrs	₹15.30m	sin datos
Kodumudi Krishnan	Additional Independent Director	2.3yrs	₹3.41m	sin datos
Alpna Seth	Independent Director	1.3yrs	sin datos	sin datos
Penny Wan	Additional Independent Director	2.3yrs	₹16.84m	sin datos
Claudio Albrecht	Director	less than a year	sin datos	sin datos

3.8yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de RDY se considera experimentada (3.8 años de antigüedad promedio).

Dr. Reddy's Laboratories Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Dr. Reddy's Laboratories Limited Announces Executive Changes

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Dr. Reddy's Laboratories Limited Announces Change in Management

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Announces Management Changes

Recent updates

Dr. Reddy's Laboratories Limited Announces Executive Changes

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

Dr. Reddy's Laboratories Limited Announces Change in Management

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed GMP and Pre-Approval Inspection

Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements

Dr. Reddy's Laboratories Ltd. Announces the Roll-Out of Nerivio in India

Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Dr. Reddy's: Growth Supported By New Labels, Profitability

Dr. Reddy's Laboratories Ltd. Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2023

Dr. Reddy's Laboratories Limited Announces Management Changes

Dr. Reddy's Laboratories Limited Announces Its Proposed Rituximab Biosimilar Application Acceptance for Review by USFDA, EMA and MHRA

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy

Dr. Reddy's Laboratories Limited Completes Phase I Study (IV Route) of DRL_TC

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 27, 2023

Dr. Reddy's Laboratories Limited Announces the Launch of Regadenoson Injection 0.4 Mg/5 Ml in the U.S

Dr. Reddy's Laboratories: Positive Q3 Results, Growth Supportive Of Buy

Dr. Reddy's Laboratories Limited Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Dr. Reddy's Laboratories Limited Completes Full Set of Clinical Studies of Its Rituximab Biosimilar for Filing in the U.S., Europe

Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed

Dr. Reddy’S Launches In-House Palbociclib (Primcyv®) to Widen Access to High-Quality Breast Cancer Drug

Dr. Reddy's Laboratories Limited Announces Resignation of Allan Grant Oberman as an Independent Director

Dr. Reddy's Laboratories Provides Updates on Litigation

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Dr. Reddy s Laboratories Ltd. Announces Tocilizumab Biosimilar Candidate, DRL_TC, Successfully Met Its Primary and Secondary Endpoints in A Phase 1 Study

Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue

Dr. Reddy's Laboratories Limited Announces Change in Directorate

Dr. Reddy's Laboratories Limited Appoints Mr. Arun Madhavan Kumar as an Independent Director

Dr. Reddy's Laboratories Limited to Report Q2, 2023 Results on Oct 28, 2022

Dr. Reddy's Laboratories Limited Informs Bruce L A Carter, Independent Director of the Company Has Ceased to Be A Director

Dr. Reddy's Laboratories Limited Appoints Arun Madhavan Kumar as an Independent Additional Director

Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 Mg Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Limited Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Dr. Reddy's launches generic drugs for allergies in US

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed Pre-Approval Inspection At Formulations Manufacturing Facility FTO 11 in Srikakulam, Andhra Pradesh

Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.

Dr. Reddy's Laboratories Limited to Report Q1, 2023 Results on Jul 28, 2022

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Dr. Reddy's Laboratories Announces the Launch of the Generic Version of Nexavar (Sorafenib) Tablets, USP, 200 Mg in the U.S. Market

Dr. Reddy’S Laboratories Ltd. Announces the Launch of Pemetrexed for Injection, 100 Mg and 500 Mg Single-Dose Vials, the Generic Equivalent of Alimta® (Pemetrexed for Injection) in the U.S. Market Approved by the U.S. Food and Drug Administration

Torrent Pharmaceuticals Limited (BSE:500420) entered into an agreement to acquire Styptovit-E, Finast, Finast-T and Dynapress brands from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 MG in the U.S. Market

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 MG in the U.S. Market

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2022

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jun 29, 2022

Dr. Reddy's Laboratories Limited Launches Posaconazole Delayed-Release Tablets in the U.S. Market

Torrent, JB Chemicals Reportedly in Final Race to Acquire Curatio Healthcare

Dr. Reddy's Laboratories Limited Announces the Launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market

Dr. Reddy's Laboratories Limited to Report Q4, 2022 Results on May 19, 2022

Dr. Reddy's Laboratories Limited to Report Q4, 2022 Results on May 19, 2022

Dr Reddy's, Biocon Reportedly Among 6 Drug Companies in Race for Curatio

Alium JSC entered into agreement to acquire Two anti-bacterial brand Ciprolet and Levolet from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT Vials in the U.S. Market

Dr. Reddy's Laboratories Limited Announces DCGI Approval to the Single-Shot Sputnik Light Vaccine in India